1
|
Frey S, Ayer A, Sotin T, Lorant V, Louis-Gaubert C, Arnaud L, Billon-Crossouard S, Croyal M, Prieur X, Hadjadj S, Cariou B, Blanchard C, Le May C. Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy improves lipid and glucose homeostasis in ob/ob mice. Obesity (Silver Spring) 2024; 32:91-106. [PMID: 37875256 DOI: 10.1002/oby.23916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Revised: 07/27/2023] [Accepted: 08/22/2023] [Indexed: 10/26/2023]
Abstract
OBJECTIVE The objective of this study was to compare the general and metabolic impact of single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) with Roux-en-Y gastric bypass (RYGB) in an obese (ob/ob) mouse model. METHODS 10-week-old male ob/ob mice underwent either SADI-S, RYGB, or laparotomy surgery (Sham group). General and metabolic parameters were assessed during a 5-week period thereafter. RESULTS SADI-S induced a deeper weight loss ([mean ± SEM] -41.2% ± 3.3%) than RYGB (-5.6% ± 3.5%, p < 0.001) compared with the Sham group (+6.3% ± 1.0%, p < 0.05). A significant food restriction was observed after SADI-S only (-31%, 117.4 ± 10.3 g vs. 170.2 ± 5.2 g of food at day 35 in Sham group mice, p < 0.001). Random-fed glycemia and glucose tolerance were more improved after SADI-S than RYGB. SADI-S decreased plasma cholesterol concentration by 60% (0.49 ± 0.04 g/L vs. 1.40 ± 0.10 g/L in the Sham group at day 35, p < 0.01), significantly more than RYGB (1.04 ± 0.14 g/L, p = 0.018). Plasma sitosterol/cholesterol and campesterol/cholesterol ratios were decreased after SADI-S, suggesting a reduced intestinal cholesterol absorption. SADI-S increased exogenous plasma cholesterol-D7 clearance and fecal elimination, also indicating an increased plasma cholesterol excretion. Studying a pair-fed group demonstrated that calorie restriction alone did not explain the beneficial impact of SADI-S. CONCLUSIONS SADI-S is associated with a greater improvement in lipid and glucose homeostasis than RYGB in ob/ob mice.
Collapse
Affiliation(s)
- Samuel Frey
- Nantes Université, CHU Nantes, CNRS, INSERM, L'institut du thorax, Nantes, France
- Nantes Université, CHU Nantes, Chirurgie Cancérologique, Digestive et Endocrinienne, Institut des Maladies de l'Appareil Digestif, Nantes, France
| | - Audrey Ayer
- Nantes Université, CHU Nantes, CNRS, INSERM, L'institut du thorax, Nantes, France
| | - Thibaud Sotin
- Nantes Université, CHU Nantes, CNRS, INSERM, L'institut du thorax, Nantes, France
| | - Victoria Lorant
- Nantes Université, CHU Nantes, CNRS, INSERM, L'institut du thorax, Nantes, France
| | - Clément Louis-Gaubert
- Nantes Université, CHU Nantes, CNRS, INSERM, L'institut du thorax, Nantes, France
- Nantes Université, CHU Nantes, Chirurgie Cancérologique, Digestive et Endocrinienne, Institut des Maladies de l'Appareil Digestif, Nantes, France
| | - Lucie Arnaud
- Nantes Université, CHU Nantes, CNRS, INSERM, L'institut du thorax, Nantes, France
| | - Stéphanie Billon-Crossouard
- Université de Nantes, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, Nantes, France
- CRNH-Ouest Mass Spectrometry Core Facility, Nantes, France
| | - Mikael Croyal
- Nantes Université, CHU Nantes, CNRS, INSERM, L'institut du thorax, Nantes, France
- Université de Nantes, CHU Nantes, Inserm, CNRS, SFR Santé, Inserm UMS 016, CNRS UMS 3556, Nantes, France
- CRNH-Ouest Mass Spectrometry Core Facility, Nantes, France
| | - Xavier Prieur
- Nantes Université, CHU Nantes, CNRS, INSERM, L'institut du thorax, Nantes, France
| | - Samy Hadjadj
- Nantes Université, CHU Nantes, CNRS, INSERM, L'institut du thorax, Nantes, France
| | - Bertrand Cariou
- Nantes Université, CHU Nantes, CNRS, INSERM, L'institut du thorax, Nantes, France
| | - Claire Blanchard
- Nantes Université, CHU Nantes, CNRS, INSERM, L'institut du thorax, Nantes, France
- Nantes Université, CHU Nantes, Chirurgie Cancérologique, Digestive et Endocrinienne, Institut des Maladies de l'Appareil Digestif, Nantes, France
| | - Cédric Le May
- Nantes Université, CHU Nantes, CNRS, INSERM, L'institut du thorax, Nantes, France
| |
Collapse
|
2
|
Ramin-Mangata S, Thedrez A, Nativel B, Diotel N, Blanchard V, Wargny M, Aguesse A, Billon-Crossouard S, Vindis C, Le May C, Hulin P, Armanet M, Gmyr V, Pattou F, Croyal M, Meilhac O, Nobécourt E, Cariou B, Lambert G. Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function. Atherosclerosis 2021; 326:47-55. [PMID: 33933263 DOI: 10.1016/j.atherosclerosis.2021.03.044] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/18/2019] [Revised: 03/09/2021] [Accepted: 03/30/2021] [Indexed: 10/21/2022]
Abstract
BACKGROUND AND AIMS Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) is an endogenous inhibitor of the LDL receptor (LDLR). Mendelian randomization studies suggest that PCSK9 deficiency increases diabetes risk, but the underlying mechanisms remain unknown. The aim of our study was to investigate whether PCSK9 or its inhibition may modulate beta cell function. METHODS We assessed PCSK9 and insulin colocalization in human pancreatic sections by epifluorescent and confocal microscopy. We also investigated the expression and the function of PCSK9 in the human EndoC-βH1 beta cell line, by ELISA and flow cytometry, respectively. PCSK9 was inhibited with Alirocumab or siRNA. LDLR expression and LDL uptake were assessed by flow cytometry. RESULTS PCSK9 was expressed and secreted from beta cells isolated from human pancreas as well as from EndoC-βH1 cells. PCSK9 secretion was enhanced by statin treatment. Recombinant PCSK9 decreased LDLR abundance at the surface of these cells, an effect abrogated by Alirocumab. Alirocumab as well as PCSK9 silencing increased LDLR expression at the surface of EndoC-βH1 cells. Neither exogenous PCSK9, nor Alirocumab, nor PCSK9 silencing significantly altered glucose-stimulated insulin secretion (GSIS) from these cells. High-low density lipoproteins (LDL) concentrations decreased GSIS, but the addition of PCSK9 or its inhibition did not modulate this phenomenon. CONCLUSIONS While PCSK9 regulates LDLR abundance in beta cells, inhibition of exogenous or endogenous PCSK9 does not appear to significantly impact insulin secretion. This is reassuring for the safety of PCSK9 inhibitors in terms of beta cell function.
Collapse
Affiliation(s)
| | - Aurélie Thedrez
- Université de Nantes, CRNH Ouest, Inra UMR 1280 PhAN, Nantes, France; L'institut du Thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France
| | - Brice Nativel
- Université de La Réunion, Inserm UMR 1188 DéTROI, Sainte Clotilde, France
| | - Nicolas Diotel
- Université de La Réunion, Inserm UMR 1188 DéTROI, Sainte Clotilde, France
| | - Valentin Blanchard
- Université de La Réunion, Inserm UMR 1188 DéTROI, Sainte Clotilde, France
| | - Matthieu Wargny
- L'institut du Thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France; CHU Nantes, INSERM, CIC 1413, Pôle Hospitalo-Universitaire 11: Santé Publique, Clinique des Données, Nantes, F-44093, France
| | - Audrey Aguesse
- Université de Nantes, CRNH Ouest, Inra UMR 1280 PhAN, Nantes, France
| | | | | | - Cédric Le May
- L'institut du Thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France
| | - Philippe Hulin
- Université de Nantes, CHU de Nantes, Inserm UMS 016, Cnrs UMS 3556, Structure Fédérative de Recherche François Bonamy, Micropicell Facility, Nantes, France
| | - Mathieu Armanet
- Cell Therapy Unit, Hôpital Saint Louis, AP-HP, Université Paris Diderot, Paris, France
| | - Valery Gmyr
- European Genomic Institute for Diabetes, Inserm UMR 1190 Translational Research for Diabetes, University of Lille 2, Lille, France
| | - François Pattou
- European Genomic Institute for Diabetes, Inserm UMR 1190 Translational Research for Diabetes, University of Lille 2, Lille, France; Lille University Hospital, Lille, France
| | - Mikaël Croyal
- Université de Nantes, CRNH Ouest, Inra UMR 1280 PhAN, Nantes, France
| | - Olivier Meilhac
- Université de La Réunion, Inserm UMR 1188 DéTROI, Sainte Clotilde, France
| | - Estelle Nobécourt
- Université de La Réunion, Inserm UMR 1188 DéTROI, Sainte Clotilde, France; CHU de La Réunion, Service d'Endocrinologie Nutrition, Saint-Pierre, France
| | - Bertrand Cariou
- L'institut du Thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France
| | - Gilles Lambert
- Université de La Réunion, Inserm UMR 1188 DéTROI, Sainte Clotilde, France.
| |
Collapse
|
3
|
Blanchard V, Garçon D, Jaunet C, Chemello K, Billon-Crossouard S, Aguesse A, Garfa A, Famchon G, Torres A, Le May C, Pichelin M, Bigot-Corbel E, Lambert G, Cariou B, Hadjadj S, Krempf M, Bach-Ngohou K, Croyal M. A high-throughput mass spectrometry-based assay for large-scale profiling of circulating human apolipoproteins. J Lipid Res 2020; 61:1128-1139. [PMID: 32404332 DOI: 10.1194/jlr.d120000835] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Revised: 05/08/2020] [Indexed: 12/20/2022] Open
Abstract
Apolipoproteins govern lipoprotein metabolism and are promising biomarkers of metabolic and cardiovascular diseases. Unlike immunoassays, MS enables the quantification and phenotyping of multiple apolipoproteins. Hence, here, we aimed to develop a LC-MS/MS assay that can simultaneously quantitate 18 human apolipoproteins [A-I, A-II, A-IV, A-V, B48, B100, C-I, C-II, C-III, C-IV, D, E, F, H, J, L1, M, and (a)] and determined apoE, apoL1, and apo(a) phenotypes in human plasma and serum samples. The plasma and serum apolipoproteins were trypsin digested through an optimized procedure and peptides were extracted and analyzed by LC-MS/MS. The method was validated according to standard guidelines in samples spiked with known peptide amounts. The LC-MS/MS results were compared with those obtained with other techniques, and reproducibility, dilution effects, and stabilities were also assessed. Peptide markers were successfully selected for targeted apolipoprotein quantification and phenotyping. After optimization, the assay was validated for linearity, lower limits of quantification, accuracy (biases: -14.8% to 12.1%), intra-assay variability [coefficients of variation (CVs): 1.5-14.2%], and inter-assay repeatability (CVs: 4.1-14.3%). Bland-Altman plots indicated no major statistically significant differences between LC-MS/MS and other techniques. The LC-MS/MS results were reproducible over five repeated experiments (CVs: 1.8-13.7%), and we identified marked differences among the plasma and serum samples. The LC-MS/MS assay developed here is rapid, requires only small sampling volumes, and incurs reasonable costs, thus making it amenable for a wide range of studies of apolipoprotein metabolism. We also highlight how this assay can be implemented in laboratories.
Collapse
Affiliation(s)
- Valentin Blanchard
- Université de La Réunion, INSERM, UMR 1188 Diabète athérothrombose Réunion Océan Indien (DéTROI), Plateforme CYROI, Saint-Denis de La Réunion, France. mailto:
| | - Damien Garçon
- L'Institut du Thorax, INSERM, CNRS, University of Nantes, Nantes, France
| | | | - Kevin Chemello
- Université de La Réunion, INSERM, UMR 1188 Diabète athérothrombose Réunion Océan Indien (DéTROI), Plateforme CYROI, Saint-Denis de La Réunion, France
| | - Stéphanie Billon-Crossouard
- NUN, INRA, CHU Nantes, UMR 1280, PhAN, IMAD, CRNH-O, Nantes, France; CRNH-O Mass Spectrometry Core Facility, Nantes, France
| | - Audrey Aguesse
- NUN, INRA, CHU Nantes, UMR 1280, PhAN, IMAD, CRNH-O, Nantes, France; CRNH-O Mass Spectrometry Core Facility, Nantes, France
| | - Aya Garfa
- CRNH-O Mass Spectrometry Core Facility, Nantes, France
| | | | - Amada Torres
- NUN, INRA, CHU Nantes, UMR 1280, PhAN, IMAD, CRNH-O, Nantes, France
| | - Cédric Le May
- L'Institut du Thorax, INSERM, CNRS, University of Nantes, Nantes, France
| | - Matthieu Pichelin
- L'Institut du Thorax, INSERM, CNRS, University of Nantes, CHU Nantes, Nantes, France
| | | | - Gilles Lambert
- Université de La Réunion, INSERM, UMR 1188 Diabète athérothrombose Réunion Océan Indien (DéTROI), Plateforme CYROI, Saint-Denis de La Réunion, France
| | - Bertrand Cariou
- L'Institut du Thorax, INSERM, CNRS, University of Nantes, CHU Nantes, Nantes, France
| | - Samy Hadjadj
- CRNH-O Mass Spectrometry Core Facility, Nantes, France; L'Institut du Thorax, INSERM, CNRS, University of Nantes, CHU Nantes, Nantes, France
| | - Michel Krempf
- NUN, INRA, CHU Nantes, UMR 1280, PhAN, IMAD, CRNH-O, Nantes, France; CRNH-O Mass Spectrometry Core Facility, Nantes, France; ELSAN, Clinique Bretéché, Nantes, France
| | - Kalyane Bach-Ngohou
- Department of Biochemistry, CHU de Nantes, France; INSERM U1235, University of Nantes, Nantes, France
| | - Mikaël Croyal
- NUN, INRA, CHU Nantes, UMR 1280, PhAN, IMAD, CRNH-O, Nantes, France; CRNH-O Mass Spectrometry Core Facility, Nantes, France
| |
Collapse
|
4
|
Croyal M, Blanchard V, Ouguerram K, Chétiveaux M, Cabioch L, Moyon T, Billon-Crossouard S, Aguesse A, Bernardeau K, Le May C, Flet L, Lambert G, Hadjadj S, Cariou B, Krempf M, Nobécourt-Dupuy E. VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May Influence Lp(a) (Lipoprotein [a]) Synthesis or Assembly. Arterioscler Thromb Vasc Biol 2020; 40:819-829. [DOI: 10.1161/atvbaha.119.313877] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Objective:
To clarify the association between PCSK9 (proprotein convertase subtilisin/kexin type 9) and Lp(a) (lipoprotein [a]), we studied Lp(a) kinetics in patients with loss-of-function and gain-of-function
PCSK9
mutations and in patients in whom extended-release niacin reduced Lp(a) and PCSK9 concentrations.
Approach and Results:
Six healthy controls, 9 heterozygous patients with familial hypercholesterolemia (5 with low-density lipoprotein receptor [
LDLR
] mutations and 4 with
PCSK9
gain-of-function mutations) and 3 patients with heterozygous dominant-negative
PCSK9
loss-of-function mutations were included in the preliminary study. Eight patients were enrolled in a second study assessing the effects of 2 g/day extended-release niacin. Apolipoprotein kinetics in VLDL (very-low-density lipoprotein), LDL (low-density lipoprotein), and Lp(a) were studied using stable isotope techniques. Plasma Lp(a) concentrations were increased in
PCSK9
-gain-of-function and familial hypercholesterolemia-
LDLR
groups compared with controls and
PCSK9
-loss-of-function groups (14±12 versus 5±4 mg/dL;
P
=0.04), but no change was observed in Lp(a) fractional catabolic rate. Subjects with
PCSK9
-loss-of-function mutations displayed reduced apoE (apolipoprotein E) concentrations associated with a VLDL-apoE absolute production rate reduction. Lp(a) and VLDL-apoE absolute production rates were correlated (
r
=0.50;
P
<0.05). ApoE-to-apolipoprotein (a) molar ratios in Lp(a) increased with plasma Lp(a) (
r
=0.96;
P
<0.001) but not with PCSK9 levels. Extended-release niacin-induced reductions in Lp(a) and VLDL-apoE absolute production rate were correlated (
r
=0.83;
P
=0.015). In contrast, PCSK9 reduction (−35%;
P
=0.008) was only correlated with that of VLDL-apoE absolute production rate (
r
=0.79;
P
=0.028).
Conclusions:
VLDL-apoE production could determine Lp(a) production and/or assembly. As PCSK9 inhibitors reduce plasma apoE and Lp(a) concentrations, apoE could be the link between PCSK9 and Lp(a).
Collapse
Affiliation(s)
- Mikaël Croyal
- From the NUN, INRA, CHU Nantes, UMR 1280, PhAN, IMAD, CRNH-O, France (M. Croyal, K.O., S.B.-C., A.A., M.K.)
- CRNH-O Mass Spectrometry Core Facility, F-44000 Nantes, France (M. Croyal, K.O., T.M., S.B.-C., A.A., M.K.)
| | - Valentin Blanchard
- Université de La Réunion, INSERM, UMR 1188 Diabète athérothrombose Réunion Océan Indien (DéTROI), Plateforme CYROI, Saint-Denis de La Réunion, France (V.B., G.L.)
| | - Khadija Ouguerram
- From the NUN, INRA, CHU Nantes, UMR 1280, PhAN, IMAD, CRNH-O, France (M. Croyal, K.O., S.B.-C., A.A., M.K.)
- CRNH-O Mass Spectrometry Core Facility, F-44000 Nantes, France (M. Croyal, K.O., T.M., S.B.-C., A.A., M.K.)
| | - Maud Chétiveaux
- L’institut du thorax, INSERM, CNRS, University of Nantes, France (M. Chétiveaux, C.L.M.)
| | - Léa Cabioch
- Biogenouest-Corsaire platform, Saint Gilles, France (L.C.)
| | - Thomas Moyon
- CRNH-O Mass Spectrometry Core Facility, F-44000 Nantes, France (M. Croyal, K.O., T.M., S.B.-C., A.A., M.K.)
| | - Stéphanie Billon-Crossouard
- From the NUN, INRA, CHU Nantes, UMR 1280, PhAN, IMAD, CRNH-O, France (M. Croyal, K.O., S.B.-C., A.A., M.K.)
- CRNH-O Mass Spectrometry Core Facility, F-44000 Nantes, France (M. Croyal, K.O., T.M., S.B.-C., A.A., M.K.)
| | - Audrey Aguesse
- From the NUN, INRA, CHU Nantes, UMR 1280, PhAN, IMAD, CRNH-O, France (M. Croyal, K.O., S.B.-C., A.A., M.K.)
- CRNH-O Mass Spectrometry Core Facility, F-44000 Nantes, France (M. Croyal, K.O., T.M., S.B.-C., A.A., M.K.)
| | - Karine Bernardeau
- P2R «Production de protéines recombinantes», CRCINA, SFR-Santé, INSERM, CNRS, UNIV Nantes, CHU Nantes, France (K.B.)
| | - Cédric Le May
- L’institut du thorax, INSERM, CNRS, University of Nantes, France (M. Chétiveaux, C.L.M.)
| | - Laurent Flet
- Pharmacy Department, Nantes University Hospital, France (L.F.)
| | - Gilles Lambert
- Université de La Réunion, INSERM, UMR 1188 Diabète athérothrombose Réunion Océan Indien (DéTROI), Plateforme CYROI, Saint-Denis de La Réunion, France (V.B., G.L.)
| | - Samy Hadjadj
- L’institut du thorax, INSERM, CNRS, University of Nantes, CHU Nantes, France (S.H., B.C.)
| | - Bertrand Cariou
- L’institut du thorax, INSERM, CNRS, University of Nantes, CHU Nantes, France (S.H., B.C.)
| | - Michel Krempf
- From the NUN, INRA, CHU Nantes, UMR 1280, PhAN, IMAD, CRNH-O, France (M. Croyal, K.O., S.B.-C., A.A., M.K.)
- CRNH-O Mass Spectrometry Core Facility, F-44000 Nantes, France (M. Croyal, K.O., T.M., S.B.-C., A.A., M.K.)
- ELSAN, clinique Bretéché, Nantes, France (M.K.)
| | | |
Collapse
|
5
|
Kaabia Z, Poirier J, Moughaizel M, Aguesse A, Billon-Crossouard S, Fall F, Durand M, Dagher E, Krempf M, Croyal M. Plasma lipidomic analysis reveals strong similarities between lipid fingerprints in human, hamster and mouse compared to other animal species. Sci Rep 2018; 8:15893. [PMID: 30367109 PMCID: PMC6203725 DOI: 10.1038/s41598-018-34329-3] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2018] [Accepted: 10/15/2018] [Indexed: 02/06/2023] Open
Abstract
Cardiovascular diseases are often associated with impaired lipid metabolism. Animal models are useful for deciphering the physiological mechanisms underlying these pathologies. However, lipid metabolism is contrasted between species limiting the transposition of findings from animals to human. Hence, we aimed to compare extended lipid profiles of several animal species to bring new insights in animal model selections. Human lipid phenotype was compared with those of 10 animal species. Standard plasma lipids and lipoprotein profiles were obtained by usual methods and lipidomic analysis was conducted by liquid chromatography-high-resolution mass spectrometry (LC-HRMS). As anticipated, we found contrasted lipid profiles between species. Some of them exhibited similar plasma lipids to human (non-human primate, rat, hamster, pig), but only usual lipid profiles of pigs were superimposable with human. LC-HRMS analyses allowed the identification of 106 other molecular species of lipids, common to all samples and belonging to major lipid families. Multivariate analyses clearly showed that hamster and, in a lower extent mouse, exhibited close lipid fingerprints to that of human. Besides, several lipid candidates that were previously reported to study cardiovascular diseases ranged similarly in human and hamster. Hence, hamster appeared to be the best option to study physiological disturbances related to cardiovascular diseases.
Collapse
Affiliation(s)
- Zied Kaabia
- Mass Spectrometry Core facility of West Human Nutrition Research Center (CRNHO), Hotel Dieu Hospital, Nantes, France
| | - Julie Poirier
- Mass Spectrometry Core facility of West Human Nutrition Research Center (CRNHO), Hotel Dieu Hospital, Nantes, France
| | - Michelle Moughaizel
- Mass Spectrometry Core facility of West Human Nutrition Research Center (CRNHO), Hotel Dieu Hospital, Nantes, France
| | - Audrey Aguesse
- Mass Spectrometry Core facility of West Human Nutrition Research Center (CRNHO), Hotel Dieu Hospital, Nantes, France.,Inra, UMR 1280, Physiologie des Adaptations Nutritionnelles, Nantes, France
| | - Stéphanie Billon-Crossouard
- Mass Spectrometry Core facility of West Human Nutrition Research Center (CRNHO), Hotel Dieu Hospital, Nantes, France.,Inra, UMR 1280, Physiologie des Adaptations Nutritionnelles, Nantes, France
| | - Fanta Fall
- Mass Spectrometry Core facility of West Human Nutrition Research Center (CRNHO), Hotel Dieu Hospital, Nantes, France
| | - Manon Durand
- Mass Spectrometry Core facility of West Human Nutrition Research Center (CRNHO), Hotel Dieu Hospital, Nantes, France
| | - Elie Dagher
- Department of Pathology, Oniris, Nantes Atlantic College of Veterinary Medicine Food Science and Engineering, Nantes, France
| | - Michel Krempf
- Mass Spectrometry Core facility of West Human Nutrition Research Center (CRNHO), Hotel Dieu Hospital, Nantes, France.,Inra, UMR 1280, Physiologie des Adaptations Nutritionnelles, Nantes, France.,Department of Endocrinology, Metabolic diseases and Nutrition, G and R Laennec Hospital, Nantes, France
| | - Mikaël Croyal
- Mass Spectrometry Core facility of West Human Nutrition Research Center (CRNHO), Hotel Dieu Hospital, Nantes, France. .,Inra, UMR 1280, Physiologie des Adaptations Nutritionnelles, Nantes, France.
| |
Collapse
|
6
|
Blanchard V, Ramin-Mangata S, Billon-Crossouard S, Aguesse A, Durand M, Chemello K, Nativel B, Flet L, Chétiveaux M, Jacobi D, Bard JM, Ouguerram K, Lambert G, Krempf M, Croyal M. Kinetics of plasma apolipoprotein E isoforms by LC-MS/MS: a pilot study. J Lipid Res 2018. [PMID: 29540575 DOI: 10.1194/jlr.p083576] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Human apoE exhibits three major isoforms (apoE2, apoE3, and apoE4) corresponding to polymorphism in the APOE gene. Total plasma apoE concentrations are closely related to these isoforms, but the underlying mechanisms are unknown. We aimed to describe the kinetics of apoE individual isoforms to explore the mechanisms for variable total apoE plasma concentrations. We used LC-MS/MS to discriminate between isoforms by identifying specific peptide sequences in subjects (three E2/E3, three E3/E3, and three E3/E4 phenotypes) who received a primed constant infusion of 2H3-leucine for 14 h. apoE concentrations and leucine enrichments were measured hourly in plasma. Concentrations of apoE2 were higher than apoE3, and concentrations of apoE4 were lower than apoE3. There was no difference between apoE3 and apoE4 catabolic rates and between apoE2 and apoE3 production rates (PRs), but apoE2 catabolic rates and apoE4 PRs were lower. The mechanisms leading to the difference in total plasma apoE concentrations are therefore related to contrasted kinetics of the isoforms. Production or catabolic rates are differently affected according to the specific isoforms. On these grounds, studies on the regulation of the involved biochemical pathways and the impact of pathological environments are now warranted.
Collapse
Affiliation(s)
- Valentin Blanchard
- CRNHO, West Human Nutrition Research Center, F-44000 Nantes, France.,INSERM, UMR 1188 DéTROI, University of La Réunion, F-97490 Sainte Clotilde, France
| | | | - Stéphanie Billon-Crossouard
- CRNHO, West Human Nutrition Research Center, F-44000 Nantes, France.,INRA, UMR 1280 PhAN, F-44000 Nantes, France
| | - Audrey Aguesse
- CRNHO, West Human Nutrition Research Center, F-44000 Nantes, France.,INRA, UMR 1280 PhAN, F-44000 Nantes, France
| | - Manon Durand
- CRNHO, West Human Nutrition Research Center, F-44000 Nantes, France.,L'institut du Thorax, INSERM, CNRS, UNIV Nantes, F-44000 Nantes, France
| | - Kevin Chemello
- INSERM, UMR 1188 DéTROI, University of La Réunion, F-97490 Sainte Clotilde, France
| | - Brice Nativel
- INSERM, UMR 1188 DéTROI, University of La Réunion, F-97490 Sainte Clotilde, France
| | - Laurent Flet
- Pharmacy Department, Nantes University Hospital, F-44093 Nantes, France
| | - Maud Chétiveaux
- CRNHO, West Human Nutrition Research Center, F-44000 Nantes, France
| | - David Jacobi
- L'institut du Thorax, INSERM, CNRS, UNIV Nantes, F-44000 Nantes, France.,L'institut du Thorax, CHU Nantes, F-44093 Nantes, France
| | - Jean-Marie Bard
- CRNHO, West Human Nutrition Research Center, F-44000 Nantes, France.,University of Nantes, Mer, Molécules, Santé (MMS) - EA 2160 and Institut Universitaire Mer et Littoral (IUML) - FR3473 CNRS, F-44000 Nantes, France, and Department of Biopathology, Institute of Cancer and Oncology, F-44800 Saint-Herblain, France
| | - Khadija Ouguerram
- CRNHO, West Human Nutrition Research Center, F-44000 Nantes, France.,INRA, UMR 1280 PhAN, F-44000 Nantes, France
| | - Gilles Lambert
- INSERM, UMR 1188 DéTROI, University of La Réunion, F-97490 Sainte Clotilde, France
| | - Michel Krempf
- CRNHO, West Human Nutrition Research Center, F-44000 Nantes, France.,INRA, UMR 1280 PhAN, F-44000 Nantes, France.,L'institut du Thorax, CHU Nantes, F-44093 Nantes, France
| | - Mikaël Croyal
- CRNHO, West Human Nutrition Research Center, F-44000 Nantes, France .,INRA, UMR 1280 PhAN, F-44000 Nantes, France
| |
Collapse
|
7
|
Croyal M, Kaabia Z, León L, Ramin-Mangata S, Baty T, Fall F, Billon-Crossouard S, Aguesse A, Hollstein T, Sullivan D, Nobecourt E, Lambert G, Krempf M. Fenofibrate decreases plasma ceramide in type 2 diabetes patients: A novel marker of CVD? Diabetes & Metabolism 2018; 44:143-149. [DOI: 10.1016/j.diabet.2017.04.003] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/08/2017] [Revised: 03/30/2017] [Accepted: 04/13/2017] [Indexed: 02/05/2023]
|
8
|
Croyal M, Billon-Crossouard S, Goulitquer S, Aguesse A, León L, Fall F, Chétiveaux M, Moyon T, Blanchard V, Ouguerram K, Lambert G, Nobécourt E, Krempf M. Stable Isotope Kinetic Study of ApoM (Apolipoprotein M). Arterioscler Thromb Vasc Biol 2017; 38:255-261. [PMID: 29146748 DOI: 10.1161/atvbaha.117.310208] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2017] [Accepted: 10/30/2017] [Indexed: 01/31/2023]
Abstract
OBJECTIVE ApoM (apolipoprotein M) binds primarily to high-density lipoprotein before to be exchanged with apoB (apolipoprotein B)-containing lipoproteins. Low-density lipoprotein (LDL) receptor-mediated clearance of apoB-containing particles could influence plasma apoM kinetics and decrease its antiatherogenic properties. In humans, we aimed to describe the interaction of apoM kinetics with other components of lipid metabolism to better define its potential benefit on atherosclerosis. APPROACH AND RESULTS Fourteen male subjects received a primed infusion of 2H3-leucine for 14 hours, and analyses were performed by liquid chromatography-tandem mass spectrometry from the hourly plasma samples. Fractional catabolic rates and production rates within lipoproteins were calculated using compartmental models. ApoM was found not only in high-density lipoprotein (59%) and LDL (4%) but also in a non-lipoprotein-related compartment (37%). The apoM distribution was heterogeneous within LDL and non-lipoprotein-related compartments according to plasma triglycerides (r=0.86; P<0.001). The relationships between sphingosine-1-phosphate and apoM were confirmed in all compartments (r range, 0.55-0.89; P<0.05). ApoM fractional catabolic rates and production rates were 0.16±0.07 pool/d and 0.14±0.06 mg/kg per day in high-density lipoprotein and 0.56±0.10 pool/d and 0.03±0.01 mg/kg per day in LDL, respectively. Fractional catabolic rates of LDL-apoM and LDL-apoB100 were correlated (r=0.55; P=0.042). Significant correlations were found between triglycerides and production rates of LDL-apoM (r=0.73; P<0.004). CONCLUSIONS In humans, LDL kinetics play a key role in apoM turnover. Plasma triglycerides act on both apoM and sphingosine-1-phosphate distributions between lipoproteins. These results confirmed that apoM could be bound to high-density lipoprotein after secretion and then quickly exchanged with a non-lipoprotein-related compartment and to LDL to be slowly catabolized.
Collapse
Affiliation(s)
- Mikaël Croyal
- From the INRA, UMR 1280, CHU Hôtel-Dieu, Faculty of Medicine, University of Nantes, France (M.C., S.B.-C., A.A., L.L., F.F., T.M., K.O., E.N., M.K.); CRNHO, West Human Nutrition Research Center, Nantes, France (M.C., S.B.-C., A.A., F.F., M.C., V.B., K.O., E.N., M.K.); INSERM-UBO, UMR 1078-ECLA, IBSAM, School of Medicine, University of Brest, France (S.G.); Biotechnology Program, National School of Medicine and Homeopathy, National Polytechnic Institute, Mexico City, Mexico (L.L.); INSERM UMR 1188 DéTROI, University of La Réunion, Sainte-Clotilde, France (G.L.); CHU de la Réunion, School of Medicine, University of la Réunion, Saint-Denis, France (E.N.); and Department of Endocrinology, Metabolic Diseases and Nutrition, G and R Laennec Hospital, Nantes, France (M.K.)
| | - Stéphanie Billon-Crossouard
- From the INRA, UMR 1280, CHU Hôtel-Dieu, Faculty of Medicine, University of Nantes, France (M.C., S.B.-C., A.A., L.L., F.F., T.M., K.O., E.N., M.K.); CRNHO, West Human Nutrition Research Center, Nantes, France (M.C., S.B.-C., A.A., F.F., M.C., V.B., K.O., E.N., M.K.); INSERM-UBO, UMR 1078-ECLA, IBSAM, School of Medicine, University of Brest, France (S.G.); Biotechnology Program, National School of Medicine and Homeopathy, National Polytechnic Institute, Mexico City, Mexico (L.L.); INSERM UMR 1188 DéTROI, University of La Réunion, Sainte-Clotilde, France (G.L.); CHU de la Réunion, School of Medicine, University of la Réunion, Saint-Denis, France (E.N.); and Department of Endocrinology, Metabolic Diseases and Nutrition, G and R Laennec Hospital, Nantes, France (M.K.)
| | - Sophie Goulitquer
- From the INRA, UMR 1280, CHU Hôtel-Dieu, Faculty of Medicine, University of Nantes, France (M.C., S.B.-C., A.A., L.L., F.F., T.M., K.O., E.N., M.K.); CRNHO, West Human Nutrition Research Center, Nantes, France (M.C., S.B.-C., A.A., F.F., M.C., V.B., K.O., E.N., M.K.); INSERM-UBO, UMR 1078-ECLA, IBSAM, School of Medicine, University of Brest, France (S.G.); Biotechnology Program, National School of Medicine and Homeopathy, National Polytechnic Institute, Mexico City, Mexico (L.L.); INSERM UMR 1188 DéTROI, University of La Réunion, Sainte-Clotilde, France (G.L.); CHU de la Réunion, School of Medicine, University of la Réunion, Saint-Denis, France (E.N.); and Department of Endocrinology, Metabolic Diseases and Nutrition, G and R Laennec Hospital, Nantes, France (M.K.)
| | - Audrey Aguesse
- From the INRA, UMR 1280, CHU Hôtel-Dieu, Faculty of Medicine, University of Nantes, France (M.C., S.B.-C., A.A., L.L., F.F., T.M., K.O., E.N., M.K.); CRNHO, West Human Nutrition Research Center, Nantes, France (M.C., S.B.-C., A.A., F.F., M.C., V.B., K.O., E.N., M.K.); INSERM-UBO, UMR 1078-ECLA, IBSAM, School of Medicine, University of Brest, France (S.G.); Biotechnology Program, National School of Medicine and Homeopathy, National Polytechnic Institute, Mexico City, Mexico (L.L.); INSERM UMR 1188 DéTROI, University of La Réunion, Sainte-Clotilde, France (G.L.); CHU de la Réunion, School of Medicine, University of la Réunion, Saint-Denis, France (E.N.); and Department of Endocrinology, Metabolic Diseases and Nutrition, G and R Laennec Hospital, Nantes, France (M.K.)
| | - Luis León
- From the INRA, UMR 1280, CHU Hôtel-Dieu, Faculty of Medicine, University of Nantes, France (M.C., S.B.-C., A.A., L.L., F.F., T.M., K.O., E.N., M.K.); CRNHO, West Human Nutrition Research Center, Nantes, France (M.C., S.B.-C., A.A., F.F., M.C., V.B., K.O., E.N., M.K.); INSERM-UBO, UMR 1078-ECLA, IBSAM, School of Medicine, University of Brest, France (S.G.); Biotechnology Program, National School of Medicine and Homeopathy, National Polytechnic Institute, Mexico City, Mexico (L.L.); INSERM UMR 1188 DéTROI, University of La Réunion, Sainte-Clotilde, France (G.L.); CHU de la Réunion, School of Medicine, University of la Réunion, Saint-Denis, France (E.N.); and Department of Endocrinology, Metabolic Diseases and Nutrition, G and R Laennec Hospital, Nantes, France (M.K.)
| | - Fanta Fall
- From the INRA, UMR 1280, CHU Hôtel-Dieu, Faculty of Medicine, University of Nantes, France (M.C., S.B.-C., A.A., L.L., F.F., T.M., K.O., E.N., M.K.); CRNHO, West Human Nutrition Research Center, Nantes, France (M.C., S.B.-C., A.A., F.F., M.C., V.B., K.O., E.N., M.K.); INSERM-UBO, UMR 1078-ECLA, IBSAM, School of Medicine, University of Brest, France (S.G.); Biotechnology Program, National School of Medicine and Homeopathy, National Polytechnic Institute, Mexico City, Mexico (L.L.); INSERM UMR 1188 DéTROI, University of La Réunion, Sainte-Clotilde, France (G.L.); CHU de la Réunion, School of Medicine, University of la Réunion, Saint-Denis, France (E.N.); and Department of Endocrinology, Metabolic Diseases and Nutrition, G and R Laennec Hospital, Nantes, France (M.K.)
| | - Maud Chétiveaux
- From the INRA, UMR 1280, CHU Hôtel-Dieu, Faculty of Medicine, University of Nantes, France (M.C., S.B.-C., A.A., L.L., F.F., T.M., K.O., E.N., M.K.); CRNHO, West Human Nutrition Research Center, Nantes, France (M.C., S.B.-C., A.A., F.F., M.C., V.B., K.O., E.N., M.K.); INSERM-UBO, UMR 1078-ECLA, IBSAM, School of Medicine, University of Brest, France (S.G.); Biotechnology Program, National School of Medicine and Homeopathy, National Polytechnic Institute, Mexico City, Mexico (L.L.); INSERM UMR 1188 DéTROI, University of La Réunion, Sainte-Clotilde, France (G.L.); CHU de la Réunion, School of Medicine, University of la Réunion, Saint-Denis, France (E.N.); and Department of Endocrinology, Metabolic Diseases and Nutrition, G and R Laennec Hospital, Nantes, France (M.K.)
| | - Thomas Moyon
- From the INRA, UMR 1280, CHU Hôtel-Dieu, Faculty of Medicine, University of Nantes, France (M.C., S.B.-C., A.A., L.L., F.F., T.M., K.O., E.N., M.K.); CRNHO, West Human Nutrition Research Center, Nantes, France (M.C., S.B.-C., A.A., F.F., M.C., V.B., K.O., E.N., M.K.); INSERM-UBO, UMR 1078-ECLA, IBSAM, School of Medicine, University of Brest, France (S.G.); Biotechnology Program, National School of Medicine and Homeopathy, National Polytechnic Institute, Mexico City, Mexico (L.L.); INSERM UMR 1188 DéTROI, University of La Réunion, Sainte-Clotilde, France (G.L.); CHU de la Réunion, School of Medicine, University of la Réunion, Saint-Denis, France (E.N.); and Department of Endocrinology, Metabolic Diseases and Nutrition, G and R Laennec Hospital, Nantes, France (M.K.)
| | - Valentin Blanchard
- From the INRA, UMR 1280, CHU Hôtel-Dieu, Faculty of Medicine, University of Nantes, France (M.C., S.B.-C., A.A., L.L., F.F., T.M., K.O., E.N., M.K.); CRNHO, West Human Nutrition Research Center, Nantes, France (M.C., S.B.-C., A.A., F.F., M.C., V.B., K.O., E.N., M.K.); INSERM-UBO, UMR 1078-ECLA, IBSAM, School of Medicine, University of Brest, France (S.G.); Biotechnology Program, National School of Medicine and Homeopathy, National Polytechnic Institute, Mexico City, Mexico (L.L.); INSERM UMR 1188 DéTROI, University of La Réunion, Sainte-Clotilde, France (G.L.); CHU de la Réunion, School of Medicine, University of la Réunion, Saint-Denis, France (E.N.); and Department of Endocrinology, Metabolic Diseases and Nutrition, G and R Laennec Hospital, Nantes, France (M.K.)
| | - Khadija Ouguerram
- From the INRA, UMR 1280, CHU Hôtel-Dieu, Faculty of Medicine, University of Nantes, France (M.C., S.B.-C., A.A., L.L., F.F., T.M., K.O., E.N., M.K.); CRNHO, West Human Nutrition Research Center, Nantes, France (M.C., S.B.-C., A.A., F.F., M.C., V.B., K.O., E.N., M.K.); INSERM-UBO, UMR 1078-ECLA, IBSAM, School of Medicine, University of Brest, France (S.G.); Biotechnology Program, National School of Medicine and Homeopathy, National Polytechnic Institute, Mexico City, Mexico (L.L.); INSERM UMR 1188 DéTROI, University of La Réunion, Sainte-Clotilde, France (G.L.); CHU de la Réunion, School of Medicine, University of la Réunion, Saint-Denis, France (E.N.); and Department of Endocrinology, Metabolic Diseases and Nutrition, G and R Laennec Hospital, Nantes, France (M.K.)
| | - Gilles Lambert
- From the INRA, UMR 1280, CHU Hôtel-Dieu, Faculty of Medicine, University of Nantes, France (M.C., S.B.-C., A.A., L.L., F.F., T.M., K.O., E.N., M.K.); CRNHO, West Human Nutrition Research Center, Nantes, France (M.C., S.B.-C., A.A., F.F., M.C., V.B., K.O., E.N., M.K.); INSERM-UBO, UMR 1078-ECLA, IBSAM, School of Medicine, University of Brest, France (S.G.); Biotechnology Program, National School of Medicine and Homeopathy, National Polytechnic Institute, Mexico City, Mexico (L.L.); INSERM UMR 1188 DéTROI, University of La Réunion, Sainte-Clotilde, France (G.L.); CHU de la Réunion, School of Medicine, University of la Réunion, Saint-Denis, France (E.N.); and Department of Endocrinology, Metabolic Diseases and Nutrition, G and R Laennec Hospital, Nantes, France (M.K.)
| | - Estelle Nobécourt
- From the INRA, UMR 1280, CHU Hôtel-Dieu, Faculty of Medicine, University of Nantes, France (M.C., S.B.-C., A.A., L.L., F.F., T.M., K.O., E.N., M.K.); CRNHO, West Human Nutrition Research Center, Nantes, France (M.C., S.B.-C., A.A., F.F., M.C., V.B., K.O., E.N., M.K.); INSERM-UBO, UMR 1078-ECLA, IBSAM, School of Medicine, University of Brest, France (S.G.); Biotechnology Program, National School of Medicine and Homeopathy, National Polytechnic Institute, Mexico City, Mexico (L.L.); INSERM UMR 1188 DéTROI, University of La Réunion, Sainte-Clotilde, France (G.L.); CHU de la Réunion, School of Medicine, University of la Réunion, Saint-Denis, France (E.N.); and Department of Endocrinology, Metabolic Diseases and Nutrition, G and R Laennec Hospital, Nantes, France (M.K.)
| | - Michel Krempf
- From the INRA, UMR 1280, CHU Hôtel-Dieu, Faculty of Medicine, University of Nantes, France (M.C., S.B.-C., A.A., L.L., F.F., T.M., K.O., E.N., M.K.); CRNHO, West Human Nutrition Research Center, Nantes, France (M.C., S.B.-C., A.A., F.F., M.C., V.B., K.O., E.N., M.K.); INSERM-UBO, UMR 1078-ECLA, IBSAM, School of Medicine, University of Brest, France (S.G.); Biotechnology Program, National School of Medicine and Homeopathy, National Polytechnic Institute, Mexico City, Mexico (L.L.); INSERM UMR 1188 DéTROI, University of La Réunion, Sainte-Clotilde, France (G.L.); CHU de la Réunion, School of Medicine, University of la Réunion, Saint-Denis, France (E.N.); and Department of Endocrinology, Metabolic Diseases and Nutrition, G and R Laennec Hospital, Nantes, France (M.K.).
| |
Collapse
|
9
|
Croyal M, Chétiveaux M, Ouguerram K, Billon-Crossouard S, Nobécourt E, Krempf M. Stable isotope kinetic study of apolipoprotein M in healthy subjects. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.07.625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
10
|
Croyal M, Bourgeois R, Ouguerram K, Billon-Crossouard S, Aguesse A, Nguyen P, Krempf M, Ferchaud-Roucher V, Nobécourt E. Comparison of gas chromatography-mass spectrometry and gas chromatography-combustion-isotope ratio mass spectrometry analysis for in vivo estimates of metabolic fluxes. Anal Biochem 2016; 500:63-5. [PMID: 26898306 DOI: 10.1016/j.ab.2016.02.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2015] [Revised: 12/31/2015] [Accepted: 02/04/2016] [Indexed: 12/11/2022]
Abstract
Gas chromatography-mass spectrometry (GC-MS) was compared with gas chromatography-combustion-isotope ratio mass spectrometry (GC-C-IRMS) for measurements of cholesterol (13)C enrichment after infusion of labeled precursor ([(13)C1,2]acetate). Paired results were significantly correlated, although GC-MS was less accurate than GC-C-IRMS for higher enrichments. Nevertheless, only GC-MS was able to provide information on isotopologue distribution, bringing new insights to lipid metabolism. Therefore, we assessed the isotopologue distribution of cholesterol in humans and dogs known to present contrasted cholesterol metabolic pathways. The labeled tracer incorporation was different in both species, highlighting the subsidiarity of GC-MS and GC-C-IRMS to analyze in vivo stable isotope studies.
Collapse
Affiliation(s)
- Mikaël Croyal
- INRA, UMR 1280, Physiologie des Adaptations Nutritionnelles, CHU Hôtel-Dieu, F-44000 Nantes, France; CRNH, Human Nutrition Research Center, CHU Hôtel-Dieu, F-44093 Nantes, France
| | - Raphaëlle Bourgeois
- INRA, UMR 1280, Physiologie des Adaptations Nutritionnelles, CHU Hôtel-Dieu, F-44000 Nantes, France; CRNH, Human Nutrition Research Center, CHU Hôtel-Dieu, F-44093 Nantes, France
| | - Khadija Ouguerram
- INRA, UMR 1280, Physiologie des Adaptations Nutritionnelles, CHU Hôtel-Dieu, F-44000 Nantes, France; CRNH, Human Nutrition Research Center, CHU Hôtel-Dieu, F-44093 Nantes, France
| | - Stéphanie Billon-Crossouard
- INRA, UMR 1280, Physiologie des Adaptations Nutritionnelles, CHU Hôtel-Dieu, F-44000 Nantes, France; CRNH, Human Nutrition Research Center, CHU Hôtel-Dieu, F-44093 Nantes, France
| | - Audrey Aguesse
- INRA, UMR 1280, Physiologie des Adaptations Nutritionnelles, CHU Hôtel-Dieu, F-44000 Nantes, France; CRNH, Human Nutrition Research Center, CHU Hôtel-Dieu, F-44093 Nantes, France
| | - Patrick Nguyen
- CRNH, Human Nutrition Research Center, CHU Hôtel-Dieu, F-44093 Nantes, France; Oniris, National College of Veterinary Medicine, Food Science, and Engineering, Nutrition and Endocrinology Unit, F-44307 Nantes, France
| | - Michel Krempf
- INRA, UMR 1280, Physiologie des Adaptations Nutritionnelles, CHU Hôtel-Dieu, F-44000 Nantes, France; CRNH, Human Nutrition Research Center, CHU Hôtel-Dieu, F-44093 Nantes, France; Endocrinology, G and R Laennec Hospital, F-44093 Nantes, France.
| | - Véronique Ferchaud-Roucher
- INRA, UMR 1280, Physiologie des Adaptations Nutritionnelles, CHU Hôtel-Dieu, F-44000 Nantes, France; CRNH, Human Nutrition Research Center, CHU Hôtel-Dieu, F-44093 Nantes, France
| | - Estelle Nobécourt
- INRA, UMR 1280, Physiologie des Adaptations Nutritionnelles, CHU Hôtel-Dieu, F-44000 Nantes, France; CRNH, Human Nutrition Research Center, CHU Hôtel-Dieu, F-44093 Nantes, France; Endocrinology, G and R Laennec Hospital, F-44093 Nantes, France
| |
Collapse
|
11
|
Croyal M, Ouguerram K, Passard M, Ferchaud-Roucher V, Chétiveaux M, Billon-Crossouard S, de Gouville AC, Lambert G, Krempf M, Nobécourt E. Effects of Extended-Release Nicotinic Acid on Apolipoprotein (a) Kinetics in Hypertriglyceridemic Patients. Arterioscler Thromb Vasc Biol 2015; 35:2042-7. [PMID: 26160958 DOI: 10.1161/atvbaha.115.305835] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2015] [Accepted: 06/24/2015] [Indexed: 11/16/2022]
Abstract
OBJECTIVE To determine the mechanisms by which extended-release nicotinic acid reduces circulating lipoprotein (a) concentrations in hypertriglyceridemic patients. APPROACH AND RESULTS Eight nondiabetic, obese male subjects (aged 48±12 years; body mass index, 31.2±1.8 kg/m(2)) with hypertriglyceridemia (triglycerides, 226±78 mg/dL) were enrolled in an 8 week, double blind, placebo-controlled cross-over study. At the end of each treatment phase, fasted subjects received a 10 µmol/L per kg bolus injection of [5,5,5-(2)H3]-l-Leucine immediately followed by constant infusion of [5,5,5-(2)H3]-l-Leucine (10 µmol L(-1) kg(-1) h(-1)) for 14 hours, and blood samples were collected. A liquid chromatography-tandem mass spectrometry method was used to study apolipoprotein (a) (Apo(a)) kinetics. The fractional catabolic rate of Apo(a) was calculated with a single compartmental model using the apolipoprotein B100 (ApoB100) containing very low density lipoprotein tracer enrichment as a precursor pool. Extended-release nicotinic acid decreased plasma triglycerides (-46%; P=0.023), raised high-density lipoprotein cholesterol (+20%; P=0.008), and decreased Apo(a) plasma concentrations (-20%; P=0.008). Extended-release nicotinic acid also decreased ApoB100 (22%; P=0.008) and proprotein convertase subtilisin/kexin type 9 (PCSK9, -29%; P=0.008) plasma concentrations. Apo(a) fractional catabolic rate and production rates were decreased by 37% (0.58±0.28 versus 0.36±0.19 pool/d; P=0.008) and 50% (1.4±0.8 versus 0.7±0.4 nmol/kg per day; P=0.008), respectively. CONCLUSIONS Extended-release nicotinic acid treatment decreased Apo(a) plasma concentrations by 20%, production rates by 50%, and catabolism by 37%. ApoB100 and PCSK9 concentrations were also decreased by treatment, but no correlation was found with Apo(a) kinetic parameters.
Collapse
Affiliation(s)
- Mikaël Croyal
- From the CRNH, West Human Nutrition Research Center, Nantes, France (M.C., K.O., M.P., V.F.-R., S.B.-C., G.L., M.K., E.N.); UMR 1280 PhAN Laboratory, National Institute of Agronomic Research, INRA, CHU Hôtel Dieu, HNB1, Nantes, France (M.C., K.O., M.P., V.F.-R., S.B.-C., G.L., M.K.); University of Nantes and Medical School, Nantes, France (M.C., K.O., M.P., M.C., S.B.-C., G.L., M.K., E.N.); GlaxoSmithKline, Les Ulis, France (A.-C.d.G.); and Endocrinology and Nutrition Department, G and R Laennec Hospital, Bd Jacques Monod, Nantes, France (M.K., E.N.)
| | - Khadija Ouguerram
- From the CRNH, West Human Nutrition Research Center, Nantes, France (M.C., K.O., M.P., V.F.-R., S.B.-C., G.L., M.K., E.N.); UMR 1280 PhAN Laboratory, National Institute of Agronomic Research, INRA, CHU Hôtel Dieu, HNB1, Nantes, France (M.C., K.O., M.P., V.F.-R., S.B.-C., G.L., M.K.); University of Nantes and Medical School, Nantes, France (M.C., K.O., M.P., M.C., S.B.-C., G.L., M.K., E.N.); GlaxoSmithKline, Les Ulis, France (A.-C.d.G.); and Endocrinology and Nutrition Department, G and R Laennec Hospital, Bd Jacques Monod, Nantes, France (M.K., E.N.)
| | - Maxime Passard
- From the CRNH, West Human Nutrition Research Center, Nantes, France (M.C., K.O., M.P., V.F.-R., S.B.-C., G.L., M.K., E.N.); UMR 1280 PhAN Laboratory, National Institute of Agronomic Research, INRA, CHU Hôtel Dieu, HNB1, Nantes, France (M.C., K.O., M.P., V.F.-R., S.B.-C., G.L., M.K.); University of Nantes and Medical School, Nantes, France (M.C., K.O., M.P., M.C., S.B.-C., G.L., M.K., E.N.); GlaxoSmithKline, Les Ulis, France (A.-C.d.G.); and Endocrinology and Nutrition Department, G and R Laennec Hospital, Bd Jacques Monod, Nantes, France (M.K., E.N.)
| | - Véronique Ferchaud-Roucher
- From the CRNH, West Human Nutrition Research Center, Nantes, France (M.C., K.O., M.P., V.F.-R., S.B.-C., G.L., M.K., E.N.); UMR 1280 PhAN Laboratory, National Institute of Agronomic Research, INRA, CHU Hôtel Dieu, HNB1, Nantes, France (M.C., K.O., M.P., V.F.-R., S.B.-C., G.L., M.K.); University of Nantes and Medical School, Nantes, France (M.C., K.O., M.P., M.C., S.B.-C., G.L., M.K., E.N.); GlaxoSmithKline, Les Ulis, France (A.-C.d.G.); and Endocrinology and Nutrition Department, G and R Laennec Hospital, Bd Jacques Monod, Nantes, France (M.K., E.N.)
| | - Maud Chétiveaux
- From the CRNH, West Human Nutrition Research Center, Nantes, France (M.C., K.O., M.P., V.F.-R., S.B.-C., G.L., M.K., E.N.); UMR 1280 PhAN Laboratory, National Institute of Agronomic Research, INRA, CHU Hôtel Dieu, HNB1, Nantes, France (M.C., K.O., M.P., V.F.-R., S.B.-C., G.L., M.K.); University of Nantes and Medical School, Nantes, France (M.C., K.O., M.P., M.C., S.B.-C., G.L., M.K., E.N.); GlaxoSmithKline, Les Ulis, France (A.-C.d.G.); and Endocrinology and Nutrition Department, G and R Laennec Hospital, Bd Jacques Monod, Nantes, France (M.K., E.N.)
| | - Stéphanie Billon-Crossouard
- From the CRNH, West Human Nutrition Research Center, Nantes, France (M.C., K.O., M.P., V.F.-R., S.B.-C., G.L., M.K., E.N.); UMR 1280 PhAN Laboratory, National Institute of Agronomic Research, INRA, CHU Hôtel Dieu, HNB1, Nantes, France (M.C., K.O., M.P., V.F.-R., S.B.-C., G.L., M.K.); University of Nantes and Medical School, Nantes, France (M.C., K.O., M.P., M.C., S.B.-C., G.L., M.K., E.N.); GlaxoSmithKline, Les Ulis, France (A.-C.d.G.); and Endocrinology and Nutrition Department, G and R Laennec Hospital, Bd Jacques Monod, Nantes, France (M.K., E.N.)
| | - Anne-Charlotte de Gouville
- From the CRNH, West Human Nutrition Research Center, Nantes, France (M.C., K.O., M.P., V.F.-R., S.B.-C., G.L., M.K., E.N.); UMR 1280 PhAN Laboratory, National Institute of Agronomic Research, INRA, CHU Hôtel Dieu, HNB1, Nantes, France (M.C., K.O., M.P., V.F.-R., S.B.-C., G.L., M.K.); University of Nantes and Medical School, Nantes, France (M.C., K.O., M.P., M.C., S.B.-C., G.L., M.K., E.N.); GlaxoSmithKline, Les Ulis, France (A.-C.d.G.); and Endocrinology and Nutrition Department, G and R Laennec Hospital, Bd Jacques Monod, Nantes, France (M.K., E.N.)
| | - Gilles Lambert
- From the CRNH, West Human Nutrition Research Center, Nantes, France (M.C., K.O., M.P., V.F.-R., S.B.-C., G.L., M.K., E.N.); UMR 1280 PhAN Laboratory, National Institute of Agronomic Research, INRA, CHU Hôtel Dieu, HNB1, Nantes, France (M.C., K.O., M.P., V.F.-R., S.B.-C., G.L., M.K.); University of Nantes and Medical School, Nantes, France (M.C., K.O., M.P., M.C., S.B.-C., G.L., M.K., E.N.); GlaxoSmithKline, Les Ulis, France (A.-C.d.G.); and Endocrinology and Nutrition Department, G and R Laennec Hospital, Bd Jacques Monod, Nantes, France (M.K., E.N.)
| | - Michel Krempf
- From the CRNH, West Human Nutrition Research Center, Nantes, France (M.C., K.O., M.P., V.F.-R., S.B.-C., G.L., M.K., E.N.); UMR 1280 PhAN Laboratory, National Institute of Agronomic Research, INRA, CHU Hôtel Dieu, HNB1, Nantes, France (M.C., K.O., M.P., V.F.-R., S.B.-C., G.L., M.K.); University of Nantes and Medical School, Nantes, France (M.C., K.O., M.P., M.C., S.B.-C., G.L., M.K., E.N.); GlaxoSmithKline, Les Ulis, France (A.-C.d.G.); and Endocrinology and Nutrition Department, G and R Laennec Hospital, Bd Jacques Monod, Nantes, France (M.K., E.N.).
| | - Estelle Nobécourt
- From the CRNH, West Human Nutrition Research Center, Nantes, France (M.C., K.O., M.P., V.F.-R., S.B.-C., G.L., M.K., E.N.); UMR 1280 PhAN Laboratory, National Institute of Agronomic Research, INRA, CHU Hôtel Dieu, HNB1, Nantes, France (M.C., K.O., M.P., V.F.-R., S.B.-C., G.L., M.K.); University of Nantes and Medical School, Nantes, France (M.C., K.O., M.P., M.C., S.B.-C., G.L., M.K., E.N.); GlaxoSmithKline, Les Ulis, France (A.-C.d.G.); and Endocrinology and Nutrition Department, G and R Laennec Hospital, Bd Jacques Monod, Nantes, France (M.K., E.N.)
| |
Collapse
|